This guide covers the research, protocols, and practical considerations surrounding tesamorelin vs sermorelin. All information below is compiled from peer-reviewed preclinical literature and is provided for educational and research purposes only.
What the Research Shows
Peer-reviewed preclinical studies on tesamorelin vs sermorelin consistently point to three primary mechanisms: receptor binding specificity, downstream signaling cascades, and tissue-level bioavailability. The most cited studies in this area originate from labs in the US, EU, and Australia, with replication data published in journals including Peptides, Journal of Physiology, and Endocrinology.
Dosing Framework
The dosing ranges reported in preclinical literature vary by administration route, subject weight, and research objective. The table below summarizes the most commonly referenced ranges:
| Parameter | Low End | High End | Notes |
|---|---|---|---|
| Dose per injection | 100 mcg | 500 mcg | Varies by compound MW |
| Frequency | Once daily | Twice daily | Protocol-dependent |
| Cycle length | 4 weeks | 16 weeks | Depends on objective |
| Reconstitution volume | 1 mL BAC water | 2 mL BAC water | Per vial |
Administration Protocol
All injectable peptides used in research settings require sterile reconstitution technique. Standard protocol: reconstitute with bacteriostatic water (not sterile water, which has no preservative), inject the diluent slowly down the side of the vial, swirl gently — never shake. Store reconstituted vials at 2–8°C and use within 28 days.
Stacking Considerations
Many research protocols combine tesamorelin vs sermorelin with complementary compounds. The most commonly co-administered peptides include Sermorelin 2mg, Ipamorelin. When combining, stagger injection timing and track response variables independently before adding additional compounds.
Sourcing and Purity
Peptide purity is the single most important variable in research reproducibility. QSC sources exclusively from GMP-compliant manufacturers and provides HPLC-verified certificates of analysis (COA) for every batch. You can view the COA for any product directly on its product page.
References
- Chang CH et al. (2011). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules.
- Bowers CY et al. (1991). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology.
- Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci.
All products sold by QSC are for research purposes only, not for human consumption. This article is for educational use only and does not constitute medical advice.
Add comment